Abstract
Objectives: Glioblastoma multiforme (GBM) may potentially be responsive to antiangiogenic therapies as these tumors are highly vascularized and overexpress angiogenic factors. Thalidomide exhibits antiangiogenic activity and may provide additive or synergistic antitumor effects when given concurrently with temozolomide, an alkylating agent. To further evaluate this new concept of combining an antiangiogenic with an alkylating agent, efficacy and tolerability of thalidomide alone and in combination with temozolomide were explored in a single-institution, nonrandomized open-label phase II study.
Patients and methods: Forty-four patients with GBMs, who received thalidomide for a period of at least three months, were evaluated for survival, time to tumor progression (TTP), and side effects. Microsurgical tumor extirpation and radiotherapy preceded chemotherapy. Nineteen patients (43%) received thalidomide only (T), and 25 patients (57%) had a combined chemotherapy of thalidomide and temozolomide (TT). Median thalidomide dosage was 200 mg/day. Median temozolomide dosage was 200 mg/m2/day for five days, in monthly cycles. Neuroradiological outcomes were assessed by a semiquantitative grading system.
Results: Median survival was 103 weeks (95% CI, 65–141 weeks) for TT-patients and 63 weeks (95% CI, 49–77 weeks) for T-patients (p < 0.01). Median TTP for the TT-group was 36 weeks (95% CI, 20–52 weeks) and 17 weeks (95% CI, 13–21 weeks) for the T-group (p < 0.06). Neuroradiologically, 14 patients (56%) of the TT-group and six (32%) of the T-group had evidence of stable disease on at least two successive neuroradiological follow-ups. Progressive disease was found in nine patients (36%) of the TT-group and in 13 (68%) of the T-group. In two patients (8%) of the TT-group, a response with tumor regression was found. Thalidomide and concurrent temozolomide were safe and well tolerated with mild to moderate toxicities.
Conclusions: The combination of thalidomide and temozolomide in the treatment of GBM appears to be more effective than that of thalidomide alone with respect to survival, TTP, and neuroradiological documentation of progression, stable disease or response. Further concurrent prospective studies of these agents in a larger group of patients with GBM will be required to establish the soundness of these intriguing observations.
Similar content being viewed by others
References
Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, Lang FF, McCutcheon IE, Hassenbusch SJ, Holland E, Hess K, Michael C, Miller D, Sawaya R: A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95: 190–198, 2001
Nieder C, Grosu AL, Molls M: A comparison of treatment results for recurrent malignant gliomas. Cancer Treat Rev 26: 397–409, 2000
Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, Levin VA, Yung WK: Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17: 2572, 1999
Surawics TS, Davis F, Freels S, Laws ER Jr, Menck HR: Brain tumor survival: results from the National Cancer Data Base. J Neuro-Oncol 40: 151–160, 1998
Prados MD, Levin V: Biology and treatment of malignant glioma. Semin Oncol 27: 1–10, 2000
Stewart LA: Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359: 1011–1018, 2002
Forsting M, Albert FK, Kunze S, Adams HP, Zenner D, Sartor K: Extirpation of glioblastomas. MR and CT follow-up of residual tumor and regrowth patterns. Am J Neuroradiol 14: 77–87, 1993
Shrieve DC, Alexander E III, Black PM, Wen PY, Fine HA, Kooy HM, Loeffler JS: Treatment of patients with primary glioblastoma multiforme with standard postoperative radiotherapy and radiosurgical boost: prognostic factors and long-term outcome. J Neurosurg 90: 72–77, 1999
Schiffer D, Chio A, Giordana MT, Mauro A, Migheli A, Vigliani MC: The vascular response to tumor infiltration in malignant gliomas. Morphometric and reconstruction study. Acta Neuropathol (Berl) 77: 369–378, 1989
Plate KH, Breier G, Weich HA, Risau W: Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359: 845–848, 1992
D'Amato RJ, Loughnan MS, Flynn E, Folkman J: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91: 4082–4085, 1994
Fine HA, Figg WD, Jaeckle K, Kyritsis AP, Loeffler JS, Levin VA, Black PM, Kaplan R, Pluda JM, Yung WK: Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 18: 708–715, 2000
Marx GM, Pavlakis N, McCowatt S, Boyle FM, Levi JA, Bell DR, Cook R, Biggs M, Little N, Wheeler HR: Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme. J Neuro-Oncol 54: 31–38, 2001
Short SC, Traish D, Dowe A, Hines F, Gore M, Brada M: Thalidomide as an anti-angiogenic agent in relapsed gliomas. J Neuro-Oncol 51: 41–45, 2001
Newlands ES, O'Reilly SM, Glaser MG, Bower M, Evans H, Brock C, Brampton MH, Colquhoun I, Lewis P, Rice-Edwards JM, Illingworth RD, Richards PG: The Charing Cross Hospital experience with temozolomide in patients with gliomas. Eur J Cancer 32A: 2236–2241, 1996
Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, Brada M, Spence A, Hohl RJ, Shapiro W, Glantz M, Greenberg H, Selker RG, Vick NA, Rampling R, Friedman H, Phillips P, Bruner J, Yue N, Osoba D, Zaknoen S, Levin VA: A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83: 588–593, 2000
Stupp R, Dietrich PY, Ostermann KS, Pica A, Maillard I, Maeder P, Meuli R, Janzer R, Pizzolato G, Miralbell R, Porchet F, Regli L, de Tribolet N, Mirimanoff RO, Leyvraz S: Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20: 1375–1382, 2002
Marx J: Angiogenesis.Aboost for tumor starvation. Science 301: 452–454, 2003
Adlard JW: Thalidomide in the treatment of cancer. Anticancer Drugs 11: 787–791, 2000
Singhal S, Mehta J: Thalidomide in cancer: potential uses and limitations. BioDrugs 15: 163–172, 2001
Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8: 1277–1280, 1990
Kleihues P, Burger PC, Collins VP, Newcomb EW, Ohgaki H, Cavanee WK: Pathology and Genetics: Tumours of the Nervous System. IARC Press (International Agency for Research on Cancer), Lyon, France 2000, pp 29–39
Wesseling P, Ruiter DJ, Burger PC: Angiogenesis in brain tumors; pathobiological and clinical aspects. J Neuro-Oncol 32: 253–265, 1997
Khan RB, Raizer JJ, Malkin MG, Bazylewicz KA, Abrey LE: A phase II study of extended low-dose temozolomide in recurrent malignant gliomas. Neuro-Oncology 4: 39–43, 2002
Moller DR, Wysocka M, Greenlee BM, Ma X, Wahl L, Flockhart DA, Trinchieri G, Karp CL: Inhibition of IL-12 production by thalidomide. J Immunol 159: 5157–5161, 1997
Flageul B, Wallach D, Cavelier-Balloy B, Bachelez H, Carsuzaa F, Dubertret L: Thalidomide and thrombosis. Ann Dermatol Venereol 127: 171–174, 2000
Brandes AA, Scelzi E, Salmistraro G, Ermani M, Carollo C, Berti F, Zampieri P, Baiocchi C, Fiorentino MV: Incidence of risk of thromboembolism during treatment high-grade gliomas: a prospective study. Eur J Cancer 33: 1592–1596, 1997
Marras LC, Geerts WH, Perry JR: The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review. Cancer 89: 640–646, 2000
Chisholm RA, Stenning S, Hawkins TD: The accuracy of volumetric measurement of high-grade gliomas. Clin Radiol 40: 17–21, 1989
Xue D, Albright RE Jr: Preoperative anaplastic glioma tumor volume effects on patient survival. J Surg Oncol 72: 199–205, 1999
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Baumann, F., Bjeljac, M., Kollias, S.S. et al. Combined Thalidomide and Temozolomide Treatment in Patients with Glioblastoma Multiforme. J Neurooncol 67, 191–200 (2004). https://doi.org/10.1023/B:NEON.0000021803.01170.03
Issue Date:
DOI: https://doi.org/10.1023/B:NEON.0000021803.01170.03